Chimerix Inc., a licensing partner of ContraVir Pharmaceuticals,
received a Notice of Allowance from the United States Patent and
Trademark Office for an extended patent life on its “Nucleoside
Phosphonate Salts” patent, which includes CMX157, an analog intended for
the treatment of hepatitis B virus infection, according to a press
release.
CMX157 is a novel lipid acyclic nucleoside
phosphonate that delivers high intracellular concentrations of Viread
(tenofovir diphosphate, ContraVir), an antiviral agent, currently being
developed for the treatment of HBV. It decreases levels of tenofovir,
lowering systemic exposure and reduces the potential for renal side
effects, according to the ContraVir website.
The patent covers the composition of matter
for CMX157 and will extend ContraVir’s intellectual property protection
of the analog through at least 2031, according to the release.
Labels: Chimerix, CMX157, Contravir